NCT00005903View on ClinicalTrials.gov

Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2000

Study Completion Date

May 31, 2005

Conditions
Progressive Supranuclear Palsy
Interventions
DRUG

GDNF & Synchro Med Infusion System

Trial Locations (1)

20892

National Institute of Neurological Disorders and Stroke (NINDS), Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00005903 - Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy | Biotech Hunter | Biotech Hunter